カテゴリ： GlobalData, アメリカ, 企業調査

Bio-Rad Laboratories Inc (BIO)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Bio-Rad Laboratories Inc (BIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8010870
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月20日
◆ページ数：65
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Bio-Rad Laboratories Inc (Bio-Rad) develops and manufactures specialty chemicals for use in biochemical, pharmaceutical and other life science research applications. The company offers a comprehensive range of reagents, apparatus, laboratory instruments, test systems, informatics systems, test kits and specialized quality controls. It offers these products to hospitals, clinical laboratories, universities, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, and food producers. The company offers its products and services to its clients though a global network of subsidiaries. The company operates in North America, Europe, Asia, the Middle East and Africa. Bio-Rad is headquartered in California, the US.

Bio-Rad Laboratories Inc (BIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Bio-Rad Laboratories Inc, Medical Devices Deals, 2011 to YTD 2017 10
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
RainDance Technologies Raises US$16.5 Million In Extended Series E Financing 13
RainDance Technologies Raises US$35 Million In Venture Financing 14
RainDance Technologies Raises US$20 Million In Series E Financing 15
GnuBio Raises US$10 Million In Series B Financing 16
GnuBio Secures US$5 Million In Second Closing Of Series A Financing 17
RainDance Technologies Secures US$37.5 Million In Series D Financing 18
Partnerships 19
AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies 19
AbD Serotec Enters Into Licensing Agreement With Proteomika 20
Genetic Analysis Enters into Agreement with Bio-Rad Labs 21
Bio-Rad Laboratories Enters into Partnership with Illumina 22
Pacific Biosciences Enters into Co-Development and Co-Marketing Agreement with RainDance Technologies 23
RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 24
RainDance Technologies Enters Into Co-Development Agreement With MLL Munchner Leukamie Labor 25
RainDance Technologies Enters Into Co-Development Agreement With Sony DADC Austria 26
AbD Serotec Enters Into Research Agreement With Dana-Farber Cancer Institute 27
Licensing Agreements 28
Vegenics Enters into Licensing Agreement with Bio-Rad Labs 28
AbD Serotec Amends Licensing Agreement With Merck 29
Asset Transactions 30
Ambry Genetics Acquires ThunderStorm System From RainDance Technologies 30
Acquisition 32
Bio-Rad Labs to Acquire RainDance Technologies 32
Bio-Rad Labs Acquires GnuBio, DNA Sequencing Technology Company 33
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 34
Bio-Rad Labs Acquires QuantaLife For US$162 Million 36
Bio-Rad Labs Acquires Additional 39% Stake In DiaMed Spain For US$3.4 Million 37
Bio-Rad Laboratories Inc – Key Competitors 38
Bio-Rad Laboratories Inc – Key Employees 39
Bio-Rad Laboratories Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 44
Financial Announcements 44
Nov 02, 2017: Bio-Rad Reports Third-Quarter 2017 Financial Results 44
Aug 03, 2017: Bio-Rad Reports Second-Quarter 2017 Financial Results 45
May 04, 2017: Bio-Rad Reports First-Quarter 2017 Financial Results 46
Mar 13, 2017: Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation Targets and Hosting an Annual Investor Day 47
Feb 23, 2017: VBio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 48
Feb 23, 2017: Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results 50
Nov 01, 2016: Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent 52
Aug 03, 2016: Bio-Rad Reports Second-Quarter 2016 Financial Results 53
May 05, 2016: Bio-Rad Reports First-Quarter 2016 Currency-Neutral Revenue Growth of Nearly 4 Percent 54
Feb 25, 2016: Bio-Rad Reports Fourth-Quarter and Full-Year 2015 Financial Results 55
Corporate Communications 57
Mar 13, 2017: Bio-Rad Intends to Propose Three New Independent Directors 57
Product News 58
Dec 04, 2017: Bio-Rad Releases First CE-IVD Digital PCR Test for Monitoring Chronic Myeloid Leukemia Response to Therapy 58
Jul 19, 2016: Bio-Rad Launches Clarity Max Western ECL Substrate 59
Jul 11, 2016: Bio-Rad Launches ddPCR CHO and E. coli Kits for Direct Quantification of Residual Host Cell DNA 60
Jun 09, 2016: Bio-Rad Laboratories released ChromLab Software Version 4.0 61
May 01, 2017: Bio-Rad Expands Its Multiplex Immunoassays with the Launch of Bio-Plex Pro Human Apolipoprotein Panel 62
Apr 19, 2017: Bio-Rad Releases Labeled Antibodies for Fluorescent Multiplex Detection of Proteins in Western Blots 63
Jan 09, 2017: Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of Complex Diseases 64
Appendix 65
Methodology 65
About GlobalData 65
Contact Us 65
Disclaimer 65

List of Tables
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Bio-Rad Laboratories Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Bio-Rad Laboratories Inc, Medical Devices Deals, 2011 to YTD 2017 10
Bio-Rad Laboratories Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
RainDance Technologies Raises US$16.5 Million In Extended Series E Financing 13
RainDance Technologies Raises US$35 Million In Venture Financing 14
RainDance Technologies Raises US$20 Million In Series E Financing 15
GnuBio Raises US$10 Million In Series B Financing 16
GnuBio Secures US$5 Million In Second Closing Of Series A Financing 17
RainDance Technologies Secures US$37.5 Million In Series D Financing 18
AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies 19
AbD Serotec Enters Into Licensing Agreement With Proteomika 20
Genetic Analysis Enters into Agreement with Bio-Rad Labs 21
Bio-Rad Laboratories Enters into Partnership with Illumina 22
Pacific Biosciences Enters into Co-Development and Co-Marketing Agreement with RainDance Technologies 23
RainDance Technologies Enters Into Co-Development Agreement With Integrated DNA Technologies For Digital PCR 24
RainDance Technologies Enters Into Co-Development Agreement With MLL Munchner Leukamie Labor 25
RainDance Technologies Enters Into Co-Development Agreement With Sony DADC Austria 26
AbD Serotec Enters Into Research Agreement With Dana-Farber Cancer Institute 27
Vegenics Enters into Licensing Agreement with Bio-Rad Labs 28
AbD Serotec Amends Licensing Agreement With Merck 29
Ambry Genetics Acquires ThunderStorm System From RainDance Technologies 30
Bio-Rad Labs to Acquire RainDance Technologies 32
Bio-Rad Labs Acquires GnuBio, DNA Sequencing Technology Company 33
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys For US$70 Million 34
Bio-Rad Labs Acquires QuantaLife For US$162 Million 36
Bio-Rad Labs Acquires Additional 39% Stake In DiaMed Spain For US$3.4 Million 37
Bio-Rad Laboratories Inc, Key Competitors 38
Bio-Rad Laboratories Inc, Key Employees 39
Bio-Rad Laboratories Inc, Other Locations 40
Bio-Rad Laboratories Inc, Subsidiaries 41

★海外企業調査レポート[Bio-Rad Laboratories Inc (BIO)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Cott Corporation：企業の戦略・SWOT・財務情報
    Cott Corporation - Strategy, SWOT and Corporate Finance Report Summary Cott Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • TDC AS：企業の戦略的SWOT分析
    TDC AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • B3 S.A.：企業の戦略・SWOT・財務分析
    B3 S.A. - Strategy, SWOT and Corporate Finance Report Summary B3 S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Total Brain Ltd (TTB)：企業の財務・戦略的SWOT分析
    Summary Total Brain Ltd (TBL) formerly, Brain Resource Ltd is a healthcare service provider that offers therapies. The company carries out research and development of brain products. TBL’s products comprise iSPOT, Total Brain and MyBrainSolutions. The company’s Total Brain is a brain health solution …
  • Sypris Solutions, Inc.：企業の戦略・SWOT・財務情報
    Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Bartlett Cocke General Contractors：企業の戦略・SWOT・財務情報
    Bartlett Cocke General Contractors - Strategy, SWOT and Corporate Finance Report Summary Bartlett Cocke General Contractors - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Ferrellgas Partners LP (FGP)：石油・ガス：M&Aディール及び事業提携情報
    Summary Ferrellgas Partners LP (Ferrellgas) is an oil and gas company that supplies propane and related equipment. The company provides transportation, wholesale marketing, and distribution of propane. It also carries out selling refined fuels and feedstocks. Ferrellgas provides propane crop drying, …
  • Peak Resources Ltd. (PEK)：企業の財務・戦略的SWOT分析
    Peak Resources Ltd. (PEK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • NovImmune SA-製薬・医療分野：企業M&A・提携分析
    Summary NovImmune SA (NovImmune) is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company develops pipeline products using its proprietary mAb generating platform, DiversityTrap and ka …
  • Zhongtian Technology Co., Ltd. (600522)：企業の財務・戦略的SWOT分析
    Zhongtian Technology Co., Ltd. (600522) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • The Straits Trading Co Ltd：企業の戦略・SWOT・財務情報
    The Straits Trading Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Straits Trading Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • OncoMed Pharmaceuticals, Inc.：企業のM&A・事業提携・投資動向
    OncoMed Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's OncoMed Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and …
  • Kaneka Corp (4118)：医療機器：M&Aディール及び事業提携情報
    Summary Kaneka Corp (Kaneka) is a chemical manufacturing company. Its product offerings include polyvinyl chloride, caustic soda, hydrochloric acid, flexible PVC compounds, rigid PVC compounds, paste PVC and chlorinated PVC. Its products include functional plastics, expandable plastics and products, …
  • Navitas Ltd：企業の戦略的SWOT分析
    Navitas Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Velocys Plc (VLS)：企業の財務・戦略的SWOT分析
    Velocys Plc (VLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Biogen Inc (BIIB)-医療機器分野：企業M&A・提携分析
    Summary Biogen Inc (Biogen) is a global biotechnology company that manufactures and markets drugs for the treatment of neurodegenerative diseases and rare and autoimmune disorders. Its marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbry …
  • RP Management LLC-製薬・医療分野：企業M&A・提携分析
    Summary RP Management LLC (RP Management) is a life sciences financing company which offers biopharmaceutical products. Its products portfolio includes rituxan, atripla, thalomid, myozyme, lexiscan, januvia, onglyza, lyrica, prezista, letairis, rotateq, cubicin, savella, neupogen, and others. The co …
  • NanoString Technologies Inc (NSTG)-製薬・医療分野：企業M&A・提携分析
    Summary NanoString Technologies Inc (NanoString) is a provider of life science products and tools for translational research and molecular diagnostics. The company's products portfolio includes sprint profiler, Dx analysis system with flex, MAX analysis system, protein assays, solid tumor assays, ge …
  • Consolidated Edison Inc (ED)：電力：M&Aディール及び事業提携情報
    Summary Consolidated Edison, Inc. (Con Edison) is an investor-owned energy company that offers wide range energy related products and services through its subsidiaries. It operates regulated electricity, gas and steam businesses, and competitive energy businesses. Con Edison’s competitive energy bus …
  • Guangzhou Wondfo Biotech Co Ltd (300482)：医療機器：M&Aディール及び事業提携情報
    Summary Guangzhou Wondfo Biotech Co Ltd (Wondfo) is a biological company that develops, manufactures and supplies rapid diagnostic reagents and related equipment. Its products include rapid quantitative test, immunofluorescent test system, glucose monitoring system, and raw materials. Wondfo also of …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆